Status:

UNKNOWN

A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions:

Primary Sjögren Syndrome

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of iguratimod compared to placebo in patients with active primary Sjogren's Syndrome.

Eligibility Criteria

Inclusion

  • meet the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism Classification Criteria for Sjogren's Syndrome (EULAR SS)
  • ESSDAI score ≥6
  • IgG \>16 g/L
  • Positive anti-SS-A/Ro antibody at screening

Exclusion

  • Pregnancy or breast feeding
  • Secondary Sjogren's syndrome
  • severe renal or haematological failure, a history of cancer, hepatitis B or C, human immunodeficiency virus, severe diabetes or any other chronic disease or evidence of infection
  • Prior administration of any of the following:
  • Rituximab in the past 12 months prior to randomization;
  • Cyclophosphamide, mycophenolate mofetil, methotrexate, leflunomide and iguratimod in the past 12 weeks prior to randomization;
  • Azathioprine, cyclosporin, tacrolimus, sirolimus, sulfasalazine in the past 4 weeks prior to randomization;
  • live vaccine in the past 12 weeks prior to randomization
  • Corticosteroids: \> 10 mg/day oral prednisone (or equivalent); Any change or initiation of new dose within 4 weeks prior to randomization; Intramuscular, subcutaneous, intravenous, or intra-articular corticosteroids within 4 weeks prior to randomization.

Key Trial Info

Start Date :

March 22 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2022

Estimated Enrollment :

144 Patients enrolled

Trial Details

Trial ID

NCT04830644

Start Date

March 22 2021

End Date

June 1 2022

Last Update

July 19 2021

Active Locations (30)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (30 locations)

1

Peking University People's Hospital

Beijing, Beijing Municipality, China, 100032

2

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

3

Southern Medical University Nanfang Hospital

Guangzhou, Guangdong, China, 510000

4

Sun Yat-sen Memorial Hospital

Guangzhou, Guangdong, China, 510000